Global Immune Cell Therapy Market Report

The forecast for the global Immune Cell Therapy market predicts substantial growth, with market size projected to soar to USD 30.85 Billion by 2033, a significant increase from the USD 4.41 Billion recorded in 2024. This expansion reflects an impressive compound annual growth rate (CAGR) of 24.13% anticipated between 2025 and 2033.

Immune Cell Therapy Market Size and Forecast 2025 to 2033

The Immune Cell Therapy market is experiencing substantial growth driven by significant advancements in biotechnological research and a burgeoning understanding of the human immune system's role in disease combat. The increasing prevalence of chronic diseases, particularly various forms of cancer, is a primary catalyst for market expansion. Innovations in gene editing technologies and cell culturing techniques are enabling the development of more potent and precise cellular therapies. Furthermore, a rising number of clinical trials investigating the efficacy of immune cell therapies across a broader spectrum of indications is contributing to the optimistic market outlook. The therapeutic potential to offer durable responses in patients who have exhausted conventional treatment options fuels significant investment and research endeavors.

Market Dynamics

Immune Cell Therapy Market Drivers

Rising Incidence of Cancer and Autoimmune Disorders: The global burden of cancer continues to escalate, creating an urgent demand for novel and effective therapeutic modalities, as reported by the World Health Organization. Immune cell therapies offer a paradigm shift from traditional treatments by harnessing the body's intrinsic defense mechanisms to target and eliminate cancerous cells. For instance, according to the National Cancer Institute, there were an estimated 1.9 million new cancer cases in the United States in 2023, highlighting the immense need for advanced treatments. Similarly, the increasing prevalence of autoimmune diseases, which affect millions globally, such as rheumatoid arthritis, lupus, and multiple sclerosis, presents a significant opportunity for immune cell therapies to restore immune homeostasis and mitigate disease progression. The Centers for Disease Control and Prevention indicate that autoimmune diseases are a leading cause of morbidity and mortality. This growing patient population, coupled with the limitations of existing treatments, propels significant investment into research and development of immune cell-based interventions.

• Advancements in Genetic Engineering and Cell Manufacturing Technologies: Breakthroughs in genetic engineering, particularly CRISPR-Cas9 and other gene-editing tools, have revolutionized the development of immune cell therapies. These technologies allow for precise modifications to immune cells, enhancing their tumor-targeting capabilities and resistance to immunosuppressive tumor microenvironments. For example, the National Institutes of Health has highlighted how gene-editing tools enable the engineering of T-cells to express chimeric antigen receptors (CARs) that specifically recognize cancer antigens. Simultaneously, significant progress in cell manufacturing and cryopreservation techniques has addressed previous limitations concerning scalability and accessibility of these complex therapies. Improved automated manufacturing processes and quality control measures are crucial for ensuring the consistency and safety of cell therapy products. This technological evolution reduces production costs and turnaround times, making these advanced therapies more viable for widespread clinical application. 
• Increasing R&D Investment and Collaborative Initiatives: The immune cell therapy market is characterized by robust research and development activities, fueled by substantial investments from both pharmaceutical companies and biotechnology firms. These investments are directed towards discovering new cell targets, optimizing cell therapy constructs, and expanding the therapeutic indications beyond oncology. According to the National Institutes of Health, significant federal funding is allocated to immunology and cancer research, underscoring the government's commitment to advancing these innovative treatments. Moreover, a growing number of strategic collaborations and partnerships between academic institutions, research organizations, and industry players are accelerating the translation of scientific discoveries into clinical applications. These collaborations facilitate knowledge sharing, resource pooling, and risk mitigation, thereby streamlining the drug development process. Such concerted efforts are vital for addressing the complex challenges associated with developing and commercializing advanced cell therapies, fostering a vibrant ecosystem for innovation and ultimately driving market growth.
• Favorable Regulatory Landscape and Expedited Approvals: Regulatory bodies across major economies are increasingly recognizing the transformative potential of immune cell therapies and are implementing expedited review pathways to accelerate their market access. Agencies such as the United States Food and Drug Administration have established programs like Breakthrough Therapy designation and Regenerated Medicine Advanced Therapy (RMAT) designation, designed to expedite the development and review of promising therapies for serious conditions. These pathways provide opportunities for early and frequent communication with regulators, allowing for a more efficient development process. The availability of these fast-track designations encourages pharmaceutical and biotechnology companies to invest in this field by offering a clearer and potentially quicker path to market approval. This proactive regulatory environment reduces the time and cost associated with drug development, making immune cell therapy a more attractive area for investment and innovation.

Immune Cell Therapy Market Opportunities

• Expansion into New Therapeutic Indications: The immense success of immune cell therapies in hematological malignancies presents a significant opportunity for their expansion into a broader range of solid tumors and autoimmune diseases. Currently, a substantial portion of research and clinical trials is focused on adapting existing immune cell therapies or developing new ones to effectively target the complex and immunosuppressive microenvironments of solid tumors, which represent a larger patient population than hematological cancers, as indicated by the National Cancer Institute. Furthermore, the immunomodulatory capabilities of certain immune cell types, such as regulatory T cells, are being explored for their potential in treating various autoimmune and inflammatory conditions. This diversification of therapeutic targets beyond oncology promises to unlock vast untapped market potential. The ability to address unmet medical needs in these diverse disease areas will significantly broaden the patient base and drive market growth.
• Development of Allogeneic "Off-the-Shelf" Therapies: A major current limitation of autologous immune cell therapies is their personalized nature, requiring a patient's own cells, which can be time-consuming, expensive, and sometimes challenging to manufacture. The development of allogeneic, "off-the-shelf" immune cell therapies, derived from healthy donors, represents a transformative opportunity. These therapies offer the potential for immediate availability, reduced manufacturing costs, and broader accessibility, making them more scalable and practical for routine clinical use, as highlighted by the National Institutes of Health's research into universal donor cells. Research is actively focused on overcoming challenges like graft-versus-host disease and improving persistence of allogeneic cells. The successful development and commercialization of allogeneic products would significantly expand the patient population eligible for immune cell therapy, streamline treatment processes, and considerably reduce the logistical burden on healthcare systems. This shift could democratize access to these advanced treatments globally.
• Integration with Combination Therapies: The potential for combining immune cell therapies with other established or emerging treatment modalities, such as chemotherapy, radiation therapy, targeted therapies, or checkpoint inhibitors, offers a promising avenue for enhancing therapeutic efficacy and overcoming resistance mechanisms. Preclinical and clinical studies are actively exploring synergistic effects when immune cell therapies are combined with these agents, leading to improved patient outcomes and more durable responses, as evidenced by numerous ongoing trials registered with the National Library of Medicine. For instance, combining CAR-T cell therapy with checkpoint inhibitors could potentially overcome the immunosuppression in the tumor microenvironment, thereby augmenting the anti-tumor activity of the CAR-T cells. This integrative approach leverages the strengths of different therapeutic strategies, potentially leading to more comprehensive and sustained anti-disease effects.
• Advancements in Gene Editing Technologies and Vector Systems: Continuous improvements in gene editing technologies, beyond initial CRISPR applications, and the development of more efficient and safer viral and non-viral vector systems for delivering genetic material into immune cells are crucial for advancing the field. Newer gene editing tools offer enhanced precision and reduced off-target effects, enabling more sophisticated engineering of immune cells for therapeutic purposes. For example, research supported by the National Institutes of Health consistently aims to refine gene delivery methods to improve the safety and efficacy of engineered cell therapies. Similarly, the development of novel vector systems, such as adeno-associated viruses (AAVs) with optimized tropism and reduced immunogenicity, is addressing current limitations in gene transfer. These technological advancements facilitate the creation of more potent, persistent, and safer immune cell therapies, overcoming previous hurdles in scalability and manufacturability. This ongoing innovation in the underlying technological infrastructure provides a fertile ground for the development of next-generation cell therapies with enhanced clinical utility.

Immune Cell Therapy Market Restrain & Challenges

• High Cost of Therapy and Reimbursement Challenges: The substantial cost associated with immune cell therapies, particularly personalized autologous treatments like CAR-T cell therapy, represents a significant barrier to widespread adoption. The complex manufacturing processes, specialized facilities, and extensive quality control measures contribute to the high price tag of these innovative treatments. For instance, a single course of CAR-T cell therapy can cost hundreds of thousands of dollars, posing a significant financial burden on healthcare systems and individual patients, as frequently discussed by the Centers for Medicare & Medicaid Services. Furthermore, securing adequate reimbursement from insurance providers and government payers remains a challenge due to the novelty and high upfront investment required for these therapies. Establishing clear and consistent reimbursement pathways is critical for market penetration and patient access. The economic strain associated with these therapies necessitates the development of more cost-effective manufacturing methods and robust real-world evidence to justify their value proposition for broader acceptance.
• Complex Manufacturing and Logistics: The production of immune cell therapies is an intricate and highly specialized process, often involving apheresis, cell expansion, genetic modification, and cryopreservation, all under stringent good manufacturing practice (GMP) conditions. This complexity presents significant logistical challenges, including ensuring the timely transportation of patient cells, maintaining cell viability throughout the process, and managing the chain of custody. According to the United States Food and Drug Administration, adherence to strict regulatory guidelines for cell and gene therapy manufacturing is paramount to ensure product quality and patient safety. Scaling up manufacturing to meet growing demand while maintaining consistent product quality and safety is a formidable task. These complexities can lead to delays, increased production costs, and potential product variability, impacting patient access and treatment efficacy. Overcoming these manufacturing and logistical hurdles requires significant investment in infrastructure, automation, and skilled personnel.
• Potential for Severe Side Effects and Toxicity: While immune cell therapies offer transformative potential, they are not without significant side effects and toxicities, which necessitate specialized management and monitoring. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are well-documented severe adverse events associated with CAR-T cell therapy, as reported by the National Cancer Institute. These toxicities can range from mild to life-threatening, requiring intensive care and experienced clinical teams for their recognition and management. The risk of these adverse events can deter healthcare providers and patients, particularly in settings without specialized infrastructure. Continued research is focused on developing strategies to mitigate these side effects, such as improved cell engineering, prophylactic medications, and better management protocols. Ensuring patient safety through comprehensive risk management strategies and patient selection remains a critical challenge for the broader adoption of these therapies.
• Limited Durability and Relapse in Certain Cancers: Despite initial impressive response rates in some hematological malignancies, a notable challenge in immune cell therapy is the potential for relapse and the limited durability of responses in certain patient populations and solid tumors. The tumor microenvironment often presents significant barriers to immune cell infiltration and function, leading to resistance mechanisms and eventual disease progression. The National Cancer Institute continuously investigates the mechanisms of resistance to immune checkpoint blockade and adoptive cell therapies. For example, in some cases, cancer cells can lose the target antigen, making them undetectable by the engineered immune cells. Overcoming these challenges requires continuous research into strategies to enhance cell persistence, improve trafficking to tumor sites, and counteract immunosuppressive factors within the tumor microenvironment. Developing more robust and long-lasting therapeutic responses is crucial for establishing immune cell therapy as a definitive treatment option across a wider range of cancers.

Current Trends in the Immune Cell Therapy Market

• Emergence of Allogeneic Cell Therapies: A significant trend in the immune cell therapy market is the accelerating development of allogeneic, "off-the-shelf" cell therapy products. Unlike autologous therapies which use a patient's own cells and are custom-manufactured for each individual, allogeneic therapies utilize cells from healthy donors, offering the potential for immediate availability and scalable production. This approach addresses key limitations of autologous therapies, such as the lengthy manufacturing times and high costs associated with personalized production. Research supported by the National Institutes of Health actively explores methods to overcome challenges associated with allogeneic therapies, such as graft-versus-host disease and immune rejection. Companies are investing heavily in technologies to engineer allogeneic cells to reduce immunogenicity and enhance their therapeutic potential, making them universally applicable. The promise of readily available and potentially more affordable treatments is driving considerable innovation and investment in this area, poised to revolutionize access to these advanced therapies.
• Integration of Gene Editing Technologies Beyond CARs: The application of advanced gene editing technologies, beyond simply engineering CARs onto T-cells, is a burgeoning trend. Researchers are leveraging tools like CRISPR-Cas9 to introduce multiple genetic modifications into immune cells, aiming to enhance their anti-tumor activity, improve persistence, and overcome resistance mechanisms within the tumor microenvironment. For instance, the National Institutes of Health highlights research into knocking out genes that contribute to T-cell exhaustion or introducing genes that secrete immune-stimulatory cytokines. This includes engineering cells to resist immunosuppressive signals from the tumor or to express novel targeting receptors. These sophisticated genetic modifications allow for the creation of "smarter" and more resilient immune cells. This trend signifies a shift towards highly engineered, multi-functional cell therapies that can address complex biological challenges, promising more effective and durable responses for a wider range of diseases.
• Focus on Solid Tumor Applications: While initial successes in immune cell therapy have primarily been observed in hematological malignancies, there is a growing and intense focus on translating these therapies to solid tumors, which represent a much larger patient population. Solid tumors present unique challenges, including a highly immunosuppressive microenvironment, heterogeneous antigen expression, and physical barriers to immune cell infiltration. The National Cancer Institute has identified the need for more effective treatments for solid tumors as a critical research priority. Companies and academic institutions are investing significantly in research and development to overcome these hurdles, exploring novel cell types, alternative targeting strategies, and combination approaches. This includes developing new CAR constructs, using tumor-infiltrating lymphocytes (TILs), or engineering natural killer (NK) cells to target specific solid tumor antigens. Success in this area would unlock a massive market opportunity and address a critical unmet medical need.
• Development of Next-Generation Immune Cell Therapies: The immune cell therapy landscape is rapidly evolving with the emergence of "next-generation" therapies that aim to improve upon existing approaches by enhancing efficacy, safety, and accessibility. This includes the exploration of diverse immune cell types beyond T-cells, such as Natural Killer (NK) cells, gamma-delta T-cells, and macrophages, for their unique therapeutic properties. The National Institutes of Health consistently funds research into the therapeutic potential of various immune cell subsets. Additionally, innovations in delivery methods, such as in vivo gene editing to create therapeutic cells directly within the patient's body, are being explored. This trend signifies a continuous drive for innovation, moving beyond the current generation of therapies to develop more potent, versatile, and patient-friendly treatments. The focus is on creating therapies with superior anti-tumor activity, reduced toxicity, and simplified administration, ultimately broadening their clinical applicability.

Segmentation Insights

Immune Cell Therapy Market Analysis, By Type

By Type, the market is segmented into T Cell Therapy, Natural Killer (NK) Cell Therapy, and Other.

• The largest segment in the Immune Cell Therapy market by type is T Cell Therapy. This dominance is primarily attributable to the groundbreaking successes achieved with Chimeric Antigen Receptor (CAR) T-cell therapies in treating various hematological malignancies. The pioneering efforts in engineering T cells to specifically target cancer cells have led to significant clinical breakthroughs, demonstrating durable remissions in patients with previously refractory diseases. The extensive research and development investment in this area, coupled with a robust pipeline of clinical trials and increasing regulatory approvals for CAR-T cell products, have solidified its leading position. The fundamental understanding of T-cell biology and their central role in adaptive immunity further contributes to their prominence in the therapeutic landscape. The established infrastructure for T-cell manufacturing and a growing pool of experienced clinicians also support its continued leadership.
• The fastest-growing segment in the Immune Cell Therapy market by type is Natural Killer (NK) Cell Therapy. This rapid growth is driven by several inherent advantages of NK cells that make them highly attractive for therapeutic development. NK cells possess an innate ability to recognize and kill cancer cells without prior sensitization or the need for specific antigen recognition, making them potentially more universally applicable and less prone to off-target toxicities compared to T-cell therapies. Furthermore, NK cells generally exhibit a favorable safety profile with a lower risk of cytokine release syndrome and graft-versus-host disease, particularly in allogeneic settings, as observed in preclinical and early clinical studies. The development of "off-the-shelf" allogeneic NK cell therapies, coupled with advancements in NK cell expansion and genetic modification techniques, is accelerating their progression through clinical development and driving significant commercial interest.

Immune Cell Therapy Market Analysis, By Application

By Application Type, the market is categorized into Stomach Cancer, Lung Cancer, Colorectal Cancer, Esophageal Cancer, Pancreatic Cancer, and Other.

• The largest segment in the Immune Cell Therapy market by application is Lung Cancer. This leading position is primarily due to the high incidence and mortality rates associated with lung cancer globally, creating an immense unmet medical need for novel and effective therapies. Lung cancer remains one of the most common and deadliest cancers, as reported by the World Health Organization, driving significant research and development efforts into innovative treatment modalities, including immune cell therapies. The complex biology of lung cancer and its often aggressive nature necessitate advanced therapeutic approaches. Furthermore, the extensive ongoing clinical trials and the increasing understanding of the immune escape mechanisms in lung cancer have paved the way for the development of targeted immune cell therapies. The substantial patient pool and the aggressive nature of the disease have garnered significant investment, making lung cancer a focal point for immune cell therapy development and adoption.
• The fastest-growing segment in the Immune Cell Therapy market by application is Pancreatic Cancer. This rapid growth is propelled by the extremely poor prognosis and limited treatment options currently available for pancreatic cancer, making it an area of critical unmet medical need. Pancreatic cancer is notoriously difficult to treat due to its highly immunosuppressive tumor microenvironment, dense stroma, and late diagnosis, as frequently highlighted by the National Cancer Institute. Immune cell therapies, particularly those designed to overcome these formidable barriers, offer a glimmer of hope for patients. The increasing focus on innovative approaches to tackle this challenging malignancy, coupled with advancements in engineering immune cells to penetrate and effectively target pancreatic tumors, is driving significant research and clinical trial activity. The urgent demand for improved outcomes in this devastating disease is fostering rapid innovation and investment in immune cell therapy solutions for pancreatic cancer.

Immune Cell Therapy Market Regional Insights

The market has been geographically analysed across five regions, Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

• The largest region in the Immune Cell Therapy market is North America. This region's dominance is attributed to several key factors, including a highly developed healthcare infrastructure, substantial research and development investments, and a robust presence of leading pharmaceutical and biotechnology companies. The United States, in particular, has been at the forefront of immune cell therapy innovation, with a significant number of clinical trials and early regulatory approvals for these advanced therapies. According to the National Institutes of Health, a substantial portion of global biomedical research funding is directed towards institutions in North America. Furthermore, a supportive regulatory environment, coupled with a high awareness and acceptance of advanced medical treatments among both healthcare providers and patients, contributes significantly to the region's market leadership. The extensive academic research base and strong venture capital funding also foster a dynamic ecosystem for the development and commercialization of immune cell therapies.
• The fastest-growing region in the Immune Cell Therapy market is Asia Pacific. This rapid growth is driven by several factors, including a large and rapidly aging population, increasing healthcare expenditure, and a rising prevalence of chronic diseases, including cancer, as reported by the World Health Organization. Countries like China, Japan, and South Korea are making significant investments in their biotechnology sectors and actively promoting research and development in advanced therapies. Furthermore, a growing number of strategic collaborations and partnerships between Western and Asian companies are facilitating technology transfer and market expansion. The increasing adoption of advanced medical technologies, coupled with a rising awareness among healthcare professionals and patients about the potential of immune cell therapies, is contributing to the region's accelerated market growth. Government initiatives aimed at promoting biomedical innovation and improving healthcare access further propel the expansion of the immune cell therapy market in the Asia Pacific region.

Immune Cell Therapy Market Competitive Overview

The Immune Cell Therapy market is characterized by intense competition and a dynamic landscape, driven by continuous innovation and a high unmet medical need. Key players are primarily focusing on research and development to expand their product pipelines, targeting new indications, and improving the efficacy and safety profiles of existing therapies. A strong emphasis is placed on developing next-generation immune cell therapies, including allogeneic approaches and gene-edited solutions, to overcome current limitations and enhance accessibility. Strategic collaborations, partnerships, and licensing agreements are prevalent as companies seek to leverage complementary expertise and accelerate clinical development. The market is also witnessing significant investment from venture capitalists and pharmaceutical giants, reflecting the immense potential of these transformative therapies. Regulatory approvals for new cell therapy products continue to reshape the competitive dynamics, with companies striving to gain first-mover advantages in specific disease areas.

Leading Market Players in the Immune Cell Therapy Market

• Novartis: Novartis is a global healthcare leader with a significant presence in the immune cell therapy market, particularly known for its pioneering role in CAR-T cell therapy. The company has made substantial investments in research and development, focusing on leveraging the body's own immune system to combat cancer and other serious diseases. Their commitment extends from fundamental research to clinical development and commercialization, aiming to bring innovative cellular therapies to patients worldwide. Novartis emphasizes the importance of patient access and has been actively involved in addressing the complexities of manufacturing and delivering these highly personalized treatments. Their strategic vision includes exploring the potential of cell therapies across a broader range of indications and continuously improving the safety and efficacy profiles of their therapeutic offerings.
• Kite Pharma: Kite Pharma, now a Gilead Company, has established itself as a frontrunner in the immune cell therapy domain, particularly recognized for its leadership in the development and commercialization of CAR-T cell therapies for hematological malignancies. The company's focus is on harnessing the power of genetically engineered T cells to deliver targeted and highly effective treatments for challenging cancers. Kite Pharma is dedicated to advancing the scientific understanding of cellular immunotherapy and expanding its clinical applications. Their efforts span from meticulous cell manufacturing processes to rigorous clinical trials, ensuring the delivery of high-quality and safe therapeutic products. The company continues to invest in research to explore new targets, enhance cell engineering techniques, and develop therapies for a wider spectrum of cancers, including solid tumors.
• Bluebird Bio: Bluebird Bio is a biotechnology company at the forefront of gene therapy and immune cell therapy, with a strong commitment to transforming the lives of patients with severe genetic diseases and certain cancers. The company's approach involves gene editing and cell engineering to correct genetic defects or empower a patient's own cells to fight disease. Bluebird Bio has a significant pipeline of innovative therapies, leveraging advanced lentiviral vector technology to deliver therapeutic genes into cells. Their research and development efforts are focused on addressing complex biological challenges and bringing highly effective and durable treatment options to patients who have limited alternatives. The company places a strong emphasis on the intricate manufacturing processes required for these advanced therapies, ensuring product consistency and quality from development to commercialization.

Top Strategies Followed by Players

• Strategic Collaborations and Partnerships: A prominent strategy employed by key players in the Immune Cell Therapy market involves forging strategic collaborations and partnerships with academic institutions, research organizations, and other biotechnology companies. These alliances facilitate knowledge sharing, resource pooling, and risk mitigation, thereby accelerating the discovery and development of novel immune cell therapies. For instance, according to the National Institutes of Health, a significant portion of breakthroughs in biomedical research results from inter-institutional collaborations, highlighting their importance in advancing complex therapeutic modalities like cell therapy. Such collaborations often encompass joint research initiatives, co-development agreements, and licensing deals, allowing companies to leverage complementary expertise, access cutting-edge technologies, and expand their therapeutic pipelines. These partnerships are crucial for navigating the complex scientific and regulatory landscape of immune cell therapy and for bringing innovative treatments to patients more efficiently.
• Investment in Research and Development for Next-Generation Therapies: Leading market players are heavily investing in extensive research and development activities focused on developing next-generation immune cell therapies. This includes exploring novel cell types beyond traditional T-cells, such as Natural Killer (NK) cells, gamma-delta T-cells, and macrophages, for their unique therapeutic properties. The National Cancer Institute consistently highlights the importance of sustained R&D investment in oncology to address unmet medical needs. Companies are also concentrating on optimizing cell engineering techniques, including advanced gene editing tools, to enhance cell persistence, improve targeting capabilities, and overcome resistance mechanisms. The goal is to develop therapies with improved efficacy, reduced toxicity, and broader applicability, particularly for challenging indications like solid tumors. This sustained commitment to R&D is critical for maintaining a competitive edge and for driving the continuous evolution of the immune cell therapy landscape.
• Expansion into Allogeneic Platforms: A significant strategic thrust among key players is the increasing focus on developing allogeneic, "off-the-shelf" immune cell therapy platforms. This strategy aims to overcome the logistical complexities, high costs, and personalized nature of autologous therapies by utilizing cells from healthy donors. Research supported by the National Institutes of Health provides insights into the advantages of allogeneic therapies in terms of scalability and accessibility. Companies are investing in technologies to minimize immunogenicity and enhance the safety and efficacy of allogeneic cell products, making them suitable for broad clinical application. The development of allogeneic therapies promises to reduce manufacturing turnaround times, lower production costs, and expand patient access, thereby significantly broadening the market for immune cell therapies. This shift represents a pivotal strategic direction, aiming to make these advanced treatments more widely available and affordable.

List of Companies Profiled in the Report are:

• Adaptimmune
• Altor Bioscience Corporation
• Cellectis
• Juno Therapeutics
• Kite Pharma
• Novartis
• Takara Bio
• Unum Therapeutics
• Bluebird Bio
• Fate Therapeutics

Global Immune Cell Therapy Market Report: Scope

List of Segments Covered

This section of the Immune Cell Therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

 By Type

• T Cell Therapy
• Natural Killer (NK) Cell Therapy
• Other

 By Application

• Stomach Cancer
• Lung Cancer
• Colorectal Cancer
• Esophageal Cancer
• Pancreatic Cancer
• Other